Category: biotech

.Accept to this week’s Chutes &amp Ladders, our summary of substantial management hirings, shootings as well as retirings all over the field. Feel free to

.Merely a handful of brief weeks after succeeding an FDA Fast Track tag for its investigational BTK degrader in specific blood stream cancers, BeiGene has

.AbbVie has come back to the source of its antipsychotic goliath Vraylar seeking yet another runaway success, spending $25 million upfront to constitute a brand-new

.On the very same day that some Parkinson’s health condition drugs are being called into question, AbbVie has actually announced that its late-stage monotherapy candidate

.Monopar Rehabs is bouncing back a drug from the scrap heap of AstraZeneca’s rare illness pipeline. It has licensed ALXN-1840, a prospect for the therapy

.AstraZeneca has actually used expert system to develop a special biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wishing to differentiate the antibody-drug conjugate (ADC)